Idarubicin Hydrochloride

• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 Phase III 13 countries Syndax Pharmaceuticals Inc.
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 Phase III 15 countries Daiichi Sankyo Inc.
• IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting
  2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion Recruiting
  2024-515456-20-00 Phase II 1 country Centre Hospitalier Universitaire De Montpellier
• Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity under anthr… Recruiting
  2025-521573-14-00 Phase IV 1 country Robert Bosch Gesellschaft fuer medizinische Forschung mbH
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting
  2024-512503-39-00 Phase IV 3 countries Medizinische Hochschule Hannover
• Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly Recruiting
  2024-513084-38-00 Phase I/II 1 country Assistance Publique Hopitaux De Paris
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 Phase III 6 countries GPOH gGmbH
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting
  2023-510240-20-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib Recruiting
  2024-513766-20-00 Phase I/II 2 countries Oxcia AB; Thomas Helledays Stiftelse Foer Medicinsk Forskning
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP… Ended
  2023-506582-58-00 Phase I (Other) 4 countries Janssen - Cilag International
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 1–14 of 14 trials